Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2022-08-09 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Approval of Financial Results (Standalone and Consolidated ) for quarter ended 30.6.2022
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Unichem Laboratories Limited dated August 9, 2022, reporting the approval of unaudited financial results for the first quarter ended June 30, 2022. It includes standalone and consolidated financial statements with detailed figures, notes on accounting policies, segment information, and auditor's review comments. The document also discusses contingent liabilities, legal matters, and significant transactions such as share purchase agreements. The presence of comprehensive financial data, including revenues, expenses, profit/loss, tax details, and earnings per share, indicates this is a quarterly financial report. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2022-08-09 English
Communication to shareholders as per Reg 30
Regulatory Filings Classification · 95% confidence The document is a press release dated August 9, 2022, announcing the receipt of ANDA approval from the USFDA for Unichem Laboratories Limited to market a generic drug. It is addressed to stock exchanges under SEBI regulations, indicating a regulatory disclosure. The content focuses on a product approval announcement rather than financial results, management changes, or detailed financial data. The document length is 3427 characters, which is relatively short and typical for a press release. There is no indication of financial statements, earnings data, or detailed report content. This fits best under the category of a Regulatory Filing (RNS), as it is a general regulatory announcement about a significant corporate event (product approval) that does not fit other specific categories like earnings release or capital update.
2022-08-09 English
ANDA approval from USFDA for Unichem's Labetalol Hydrochloride Tablets
Regulatory Filings Classification · 95% confidence The document is a press release dated August 9, 2022, announcing the receipt of ANDA approval from the USFDA for Unichem Laboratories Limited's Labetalol Hydrochloride Tablets. It is addressed to stock exchanges under SEBI regulations and includes contact information and a disclaimer about forward-looking statements. The document is short (3427 characters) and primarily serves as an announcement of a regulatory approval event, not a financial report or detailed filing. There is no financial data, no management discussion, no voting results, no audit information, or other detailed report content. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a significant corporate event (FDA approval).
2022-08-09 English
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 ,inter alia, to consider and approve Unaudited Financial Results ....
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve unaudited financial results for the quarter ended June 30, 2022. It is addressed to stock exchanges and informs about the meeting date and trading window closure. The document does not contain actual financial data or results but is an announcement of an upcoming event related to financial reporting. The length is short (1719 characters), and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2022-08-01 English
Board Meeting — Financial results
Regulatory Filings Classification · 95% confidence The document is a notice from Unichem Laboratories Limited informing the stock exchanges about an upcoming Board Meeting scheduled for August 9, 2022. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended June 30, 2022. The document also mentions the closure of the trading window for insiders as per SEBI regulations. The document is short (1719 characters) and serves as an announcement of a board meeting rather than containing any financial results or detailed reports. Therefore, it is not an Interim/Quarterly Report (IR) itself but a notice about the meeting where such results will be approved. This fits the category of Regulatory Filings (RNS), which includes general regulatory announcements and compliance documents that do not fit other specific categories.
2022-08-01 English
Newspaper Advertisements
AGM Information Classification · 95% confidence The document is a notice regarding the 59th Annual General Meeting (AGM) of Unichem Laboratories Limited, including details about remote e-voting, book closure dates, and the availability of the Annual Report for the year ended 31st March 2022. It includes procedural information about the AGM, voting rights, and electronic voting instructions. The document is primarily a notice and advertisement for the AGM and related voting procedures, not the full Annual Report itself. It also references the Annual Report being available on the company's website and stock exchange websites, indicating this document is an announcement related to the AGM and voting, not the report itself. Therefore, the document fits the category of AGM Information (AGM-R) rather than the Annual Report (10-K) or Report Publication Announcement (RPA).
2022-07-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.